Treatment options in patients with pancreatic cancer: A 10-year multicenter epidemiological investigation in China
In China, pancreatic cancer is often diagnosed at advanced stages, emphasizing the need for early diagnosis and treatment. Combined therapies in adjuvant and first-line settings may reduce the risk of death compared with monotherapy, and FOLFIRINOX might offer more significant benefits in second-line treatment.
Authors
- Shui-Sheng Zhang
- Jin‐Hu Fan (ORCID: https://orcid.org/0000-0003-3159-7893)
- Rufu Chen (ORCID: https://orcid.org/0009-0009-3479-8595)
- Wanyi Sun
- Jun Liu (ORCID: https://orcid.org/0000-0002-6511-029X)
- Bin Zhou (ORCID: https://orcid.org/0000-0002-8076-0960)
- Shaokai Zhang (ORCID: https://orcid.org/0000-0002-0154-7126)
- Shengping Li (ORCID: https://orcid.org/0000-0002-8309-4078)
- Chengfeng Wang (ORCID: https://orcid.org/0000-0003-2931-9085)
- Renyi Qin (ORCID: https://orcid.org/0000-0002-1950-0940)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-08-13
- DOI
- https://doi.org/10.4251/wjgo.v17.i8.106447
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00